GlassScriptPhysician profile
Ashley L Clark
NPI 1588171904
$3,593.14
in general payments reported to CMS, 2019-2025
15 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $672 · 2022: $709 · 2023: $550 · 2024: $500 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $944.76 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $733.01 | 2021-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $445.25 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $266.56 | 2025 | Tremfya |
| Fujifilm Healthcare Americas Corporation | $187.86 | 2023 | Fujifilm |
| Madrigal Pharmaceuticals | $145.61 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $141.85 | 2022-2025 | Livdelzi |
| Lucid Diagnostics INC. | $140.37 | 2025 | |
| Qol Medical, LLC | $139.15 | 2024 | Sucraid |
| Genzyme Corporation | $132.80 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $118.15 | 2024 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $116.37 | 2025 | Voquezna |
| Vivus LLC | $40.98 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.61 | 2022 | |
| Avion Pharmaceuticals | $18.81 | 2023 | Balcoltra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.